Ligand ventures into OmniAb platform license agreement with Ferring Pharmaceuticals

Ligand Pharmaceuticals asserted that it has forayed into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. As per the terms of the agreement, Ferring authorises to utilise OmniRat, OmniMouse, OmniFlic and OmniChicken to discover fully human mono- and bispecific antibodies.

John Higgins, Chief Executive Officer of Ligand stated “There is significant demand for research tools to facilitate drug discovery, and our novel platform of transgenic animals, proprietary assays and intellectual property make our offering a very attractive package for licensing. We continue to invest in the platform and secure more deals that will drive Ligand’s future growth.”

Ligand is liable for annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Ferring will bear all the costs related to the programs.